Welcome to our dedicated page for Inovio Pharmaceuticals news (Ticker: INO), a resource for investors and traders seeking the latest updates and insights on Inovio Pharmaceuticals stock.
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) is a pioneering United States-based biotechnology company dedicated to combating cancers and infectious diseases through DNA medicines. The company's innovative approach harnesses active DNA-based immunotherapies and vaccines to both treat and prevent these conditions.
Inovio's core technology revolves around its DNA plasmids, which are small circular DNA molecules crafted to produce specific proteins to target and fight diseases, delivered via their proprietary CELLECTRA® electroporation devices. This technology enables the body to produce its own disease-fighting proteins and immune responses, without the need for traditional adjuvants or nanoparticles.
The company's flagship candidate, INO-3107, targets Recurrent Respiratory Papillomatosis (RRP), a chronic and rare disease caused by HPV-6 and HPV-11. Inovio has shown significant clinical progress with INO-3107, and after receiving Breakthrough Therapy designation and Orphan Drug designation from both the FDA and the European Commission, it is on track to submit a Biologics License Application (BLA) under the FDA's accelerated approval program. With successful clinical trials demonstrating a robust immune response and a reduction in the need for surgical interventions, INO-3107 stands as a potential game-changer for RRP patients.
In addition to INO-3107, Inovio's expansive product pipeline includes several other promising candidates in various stages of development. These include INO-3112 for HPV-16/18 positive head and neck cancer, INO-4201 as an Ebola vaccine booster, and INO-5401 for glioblastoma, showcasing the versatility and broad applicability of the company's DNA medicine platform.
Inovio has established numerous strategic partnerships and collaborations to enhance its research and development efforts. Key partners include Roche, MedImmune, the University of Pennsylvania, DARPA, Drexel University, NIH, and the U.S. Military HIV Research Program. These collaborations not only bolster Inovio's scientific capabilities but also facilitate the swift advancement of its clinical programs.
Financially, Inovio has maintained a disciplined approach to managing its resources. The company recently projected its cash runway to extend into the second quarter of 2025, following positive feedback from the FDA on the accelerated approval pathway for INO-3107. This financial stability is crucial as Inovio prepares for potential commercialization of its lead candidates.
Inovio's commitment to innovation and its effective strategic execution position it as a formidable player in the biopharmaceutical industry, dedicated to bringing groundbreaking DNA medicine solutions to market. For more information, visit www.inovio.com.
INOVIO (NASDAQ: INO) announced positive interim results from a Phase 1/2 trial of INO-3107 for treating HPV 6 and HPV 11-associated Recurrent Respiratory Papillomatosis (RRP). Out of 21 participants, 76% saw a reduction in surgical interventions compared to the previous year, with 6 participants surgery-free. INO-3107 also demonstrated statistical significance in its primary endpoint and was well-tolerated. The treatment induced both CD4 and CD8 T cell responses against HPV types, suggesting potential as a first-in-class therapeutic option for RRP.
INOVIO (NASDAQ: INO) announced equity grants to two newly hired employees, including a Vice President of Clinical Development, on August 31, 2022. The grants comprise 5,000 restricted stock units (RSUs) and options for 26,250 shares of common stock, approved by the Compensation Committee under the 2022 Inducement Plan. The RSUs will vest over three years, and the stock options have an exercise price of $2.29, aligned with the stock's closing price on the Grant Date.
INOVIO (NASDAQ:INO), a biotechnology company focused on DNA medicines, announced that President and CEO Jacqueline Shea, Ph.D., will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, starting at 7:00 AM ET. The conference will feature one-on-one meetings with registered investors and a webcast available on the INOVIO Investor Relations Events page, with replays accessible for 90 days post-event. INOVIO specializes in developing treatments for infectious diseases and cancer.
INOVIO (NASDAQ: INO) announced financial results for Q2 2022, reporting revenue of $784,000, up from $273,000 in Q2 2021. The company extended its cash runway into Q3 2024 through a corporate restructuring, involving an 18% workforce reduction and expected 30% reduction in operating expenses. Positive data from a Phase 1/2 trial of INO-5401 for glioblastoma was presented at ASCO. Despite these advancements, net loss widened to $108.5 million, or $0.46 per share, from $82.1 million, or $0.39 per share, in the prior year.
INOVIO (NASDAQ:INO) will release its second quarter 2022 financial results on August 9, 2022, after market close. Following the release, the company will host a live conference call and webcast at 4:30 p.m. EDT to discuss the results and provide an update on its business. Focused on DNA medicines for infectious diseases and cancer, INOVIO utilizes a proprietary smart device for vaccine delivery. For more information, visit www.inovio.com.
INOVIO (NASDAQ: INO) has announced a corporate reorganization aimed at cutting operational expenses by around 30% over the next 18 months. The restructuring involves an 18% reduction in full-time employees and an 86% cut in contractors, expected to extend the company's cash runway into Q3 2024. A one-time restructuring charge of approximately $1.6 million is anticipated. The cost-saving measures will allow the company to concentrate on key clinical programs, including its COVID-19 vaccine candidate and HPV initiatives, enhancing its growth prospects in the biotech sector.
INOVIO (NASDAQ: INO) announced the approval of equity grants to Dr. Michael John Sumner, the newly appointed Chief Medical Officer, as part of its 2022 Inducement Plan. The grants included a restricted stock unit (RSU) award of 105,000 shares, vesting over three years, and a stock option to purchase 160,000 shares at an exercise price of $1.73. Both awards are contingent on Dr. Sumner's continued employment. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects INOVIO's commitment to attract top talent in biotechnology.
INOVIO (NASDAQ: INO) has appointed Dr. Michael Sumner as its new Chief Medical Officer. With over 25 years of experience in clinical development and regulatory affairs, Dr. Sumner will oversee INOVIO's clinical-stage pipeline, including clinical operations and regulatory affairs. He previously served as CMO of Orexo AB and held roles at Novartis Pharmaceuticals and other major pharmaceutical companies. His expertise in guiding companies through product approvals is expected to bolster INOVIO's efforts in developing DNA medicines aimed at infectious diseases and cancers.
INOVIO (NASDAQ: INO) announced promising results from a Phase 1/2 trial evaluating INO-5401 and INO-9012 in combination with Libtayo® for newly diagnosed glioblastoma (GBM). The study reported a median overall survival (OS) of 32.5 months for MGMT methylated patients, outperforming historical data. The combination therapy showed a tolerable safety profile and elicited immune responses, with activated T cells identified. Dr. David Reardon will present these findings at ASCO on June 6, 2022, emphasizing the potential of this novel treatment approach for GBM patients.
INOVIO (NASDAQ: INO) announced that President and CEO Jacqueline Shea, along with Jeffrey Skolnik, SVP of Clinical Development for Oncology and HPV Therapeutics, will participate in a fireside chat and individual investor meetings at the Jefferies 2022 Healthcare Conference on June 8, 2022, at 1:00 PM EDT. A webcast of the presentation will be available on the INOVIO Investor Relations Events page. The company focuses on developing DNA medicines for infectious diseases, cancer, and HPV-associated diseases.
FAQ
What is the current stock price of Inovio Pharmaceuticals (INO)?
What is the market cap of Inovio Pharmaceuticals (INO)?
What is Inovio Pharmaceuticals' primary focus?
What is INO-3107?
What is the CELLECTRA® device?
Who are some of Inovio’s key partners?
What financial outlook has Inovio projected?
What is INO-3112?
How does Inovio's DNA medicines platform work?
What are some of Inovio’s recent achievements?
Where can I find more financial information about Inovio?
What is Inovio's approach to commercialization?
